NCT06867822: A trial that was reported late by University of Alabama at Birmingham
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT06867822 |
|---|---|
| Title | A Phase I/Ib Trial of ProAgio, an Anti-avb3 Integrin Cytotoxin, in Combination with 5-fluorouracil , Irinotecan and Bevacizumab for Advanced/metastatic Colorectal Cancer (ProAgio in CRC) |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 30, 2025 |
| Completion date | July 31, 2027 |
| Required reporting date | July 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 3, 2025 |
| Days late | None |